Browse By: Country ι Category ι Latest Reports ι Tag
Home  »  GBI Research

GBI Research Market Research Reports

GBI Research provides industry-leading global business intelligence solutions. Our products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports per annum across a wide range of industries. Our reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from our expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia. Key report types currently published by GBI Research include:

  • Market Intelligence Reports: premium analytical reports based on a combination of market data, company, deals and project content, industry surveys and additional primary and secondary research.
  • Benchmarking Reports: analytical reports comparing key financial indicators for the top 20 companies in a particular industry and geography.
  • Industry Outlook Reports: survey-based reports, revealing and analyzing the leading experts' opinions on the future of the industry covered.
  • Market Profiles: overview-level reports based on market, company and demographic data.
  • Pipeline Analysis Reports: reports analyzing the unmet need, market size and product pipeline for different disease indications, based on a detailed database of developmental products.



Stem Cell Therapies - Global Trends in the Competitive, Technological and R&D Landscape
GBI Research’s latest report, ""Stem Cell Therapies - Global Trends in the Competitive, Technological and R&D Landscape"" provides an in-depth assessment of the current trends in the global stem cell therapy sector with a particular focus on the technological, competitive and R&D landscape. Along extensive secondary research efforts, GBI research conducted a targeted industry survey of experts and key opinion leaders in the stem cell therapies field to gather opinions on the global trends and future commercial prospects of the stem cell therapies market.
Published Date: Jul 2016
Published By: GBI Research

Price: $2995
Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies
Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence - it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030.
Published Date: Jun 2016
Published By: GBI Research

Price: $6995
Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics
Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer - the key indications covered in this report - accounting for the majority of that figure. 
Published Date: Jun 2016
Published By: GBI Research

Price: $4995
Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline
GBI Research’s latest report: “Innovation Tracking Factbook 2016: An Assessment of the Pharmaceutical Pipeline” is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. 
Published Date: Jun 2016
Published By: GBI Research

Price: $2995
Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies
Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow, and include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating that lymphomas are more prevalent than leukemia or myeloma.
Published Date: Jun 2016
Published By: GBI Research

Price: $6995
Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth
Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition.For the past decades, the majority of the dermatology market has remained saturated with established products. 
Published Date: May 2016
Published By: GBI Research

Price: $4995
Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer.
Published Date: May 2016
Published By: GBI Research

Price: $4995
Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market
Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma.
Published Date: Apr 2016
Published By: GBI Research

Price: $4995
Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics
Viruses are infectious particles comprising a nucleic acid core – consisting of either DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by exploiting the resources of their host cells, usually to the detriment of the host.
Published Date: Apr 2016
Published By: GBI Research

Price: $4995
Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms
Schizophrenia is a severe mental disorder that is characterized by abnormal social behavior and failure to recognize what is real; its symptoms are broadly divided into positive, negative and cognitive. The treatment of schizophrenia is multi-factorial and includes medical, psychological and psychosocial inputs. 
Published Date: Apr 2016
Published By: GBI Research

Price: $6995
Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics
In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.
Published Date: Apr 2016
Published By: GBI Research

Price: $4995
Substance Abuse Deterrents and Treatments - An Assessment of the Technological, Competitive and R&D Landscape
​GBI Research's latest report, ""Substance Abuse Deterrents and Treatments - An Assessment of the Technological, Competitive and R&D Landscape"", discusses global trends in the substance abuse deterrents and addiction treatments market including the impact substance abuse is having on local economies, healthcare systems and society as a whole. 
Published Date: Mar 2016
Published By: GBI Research

Price: $2995
Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs
Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide.
Published Date: Mar 2016
Published By: GBI Research

Price: $6995
Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies
Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies", provides key insights into the global telehealth regulatory and market landscape, as well as its main applications in healthcare and associated sectors.
Published Date: Mar 2016
Published By: GBI Research

Price: $2995
Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns
Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.
Published Date: Mar 2016
Published By: GBI Research

Price: $4995
Alzheimers Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies
Alzheimers Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. 
Published Date: Mar 2016
Published By: GBI Research

Price: $4995
Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes
The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape.
Published Date: Feb 2016
Published By: GBI Research

Price: $6995
Parkinsons Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments
Parkinson's Disease (PD) is a progressive, chronic neurodegenerative condition, which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the substantia nigra region of the brain.
Published Date: Feb 2016
Published By: GBI Research

Price: $4995
Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these.
Published Date: Jan 2016
Published By: GBI Research

Price: $4995
Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation
Parkinson’s Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, affecting around 7.4 million people worldwide. It is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia. 
Published Date: Jan 2016
Published By: GBI Research

Price: $6995
Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation
​Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the world. 
Published Date: Dec 2015
Published By: GBI Research

Price: $6995
Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence
​Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. 
Published Date: Dec 2015
Published By: GBI Research

Price: $4995
Biobanking: Developing Smart, Sustainable and Ethically Compliant Biorepositories for the Future
"Biobanking: Developing Smart, Sustainable and Ethically Compliant Biorepositories for the Future" discusses fundamental concepts in biobanking and recent technology advancements in the field.
Published Date: Dec 2015
Published By: GBI Research

Price: $2995
Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth
Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response.
Published Date: Dec 2015
Published By: GBI Research

Price: $4995
Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation
​Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. 
Published Date: Dec 2015
Published By: GBI Research

Price: $6995
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
​Pancreatic Cancer (PC) is a disease predominately of the elderly with ~75% of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is asymptomatic at its earliest stages and when symptoms do present themselves they are non-specific.
Published Date: Dec 2015
Published By: GBI Research

Price: $4995
COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands
​Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world.
Published Date: Nov 2015
Published By: GBI Research

Price: $4995
Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations
​Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response.
Published Date: Nov 2015
Published By: GBI Research

Price: $4995
Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth
Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of PC cases are diagnosed at an early stage (60%).
Published Date: Nov 2015
Published By: GBI Research

Price: $4995
Pharmaceutical Deal Trends (2010-2015) and In-Depth Analysis of Recent Deal Activity
GBI Research’s latest report: “Pharmaceutical Deal Trends (2010–2015) and In-Depth Analysis of Recent Deal Activity” discusses deal-making trends for a range of deal types, such as Mergers & Acquisitions (M&A) and strategic alliances. It also examines preference by deal type, along with disclosed deal values from 2010 to July 2015, covering start-ups, mid-level players, and big players.
Published Date: Oct 2015
Published By: GBI Research

Price: $2995
Myeloma Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments
Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology.
Published Date: Oct 2015
Published By: GBI Research

Price: $4995
Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments
​Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology.
Published Date: Oct 2015
Published By: GBI Research

Price: $4995
Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation
​Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared.
Published Date: Oct 2015
Published By: GBI Research

Price: $6995
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment landscape based on different NSCLC subtypes and the presence of various molecular aberrations. 
Published Date: Sep 2015
Published By: GBI Research

Price: $4995
Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth
Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries.
Published Date: Sep 2015
Published By: GBI Research

Price: $4995
Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended for aggressive disease. 
Published Date: Aug 2015
Published By: GBI Research

Price: $6995
Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets. This has led to strong commercial interest in the development of T2DM therapeutics. The current market is large and diverse, comprising several drug classes, including generic and branded drugs. Owing to the range of therapeutic options available, the treatment algorithm is complex. However, current treatment regimens are often
Published Date: Jul 2015
Published By: GBI Research

Price: $4995
Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation
The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,484 products in active development across all oncology indications, and 2,084 first-in-class products in development across all stages. Due to a degree of crossover between oncology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs test
Published Date: Jul 2015
Published By: GBI Research

Price: $6995
Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments
Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10–15 years, and have improved median survival rates by about 50%. The MM pipeline contains 267 products in active development, encompassing a range of molecule types and therapeutic targets. The innovation that has characterized the market over recent years is also clearly present in the current pipeline, with a
Published Date: Jul 2015
Published By: GBI Research

Price: $4995
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control. The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin inhibitors, and diuretics. The p
Published Date: Jul 2015
Published By: GBI Research

Price: $4995
Contract Research Organization Market - Global Deals and Operational Strategies
GBI Research’s latest report “Contract Research Organization Market: Global Deals and Operational Strategies” discusses the deal making activity during the past five years and in-depth analysis of the key deals involving more than 40 public and privately held CROs. The operational strategies adopted by key players in the recent years have been listed. A heatmap analysis of the key companies was done based on their firm utilization and capital management. SWOT analysis and profiles are given for the key companies in the market. Companies mentioned in the report are Quintiles, Covance, Parexel, Catalent, ICON, PRA Health, Charles River, INC Research, WuXi PharmaTech, CMIC Holdings, EPS Corporation, Recipharm, Novotech, Laboratory Corporation of America Holdings, Consort
Published Date: Jun 2015
Published By: GBI Research

Price: $2995
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market. A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market. Within the pipeline, there are 185 products that act on a first-in-class molecular target, representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. A drastically different pipeline and market composition impl
Published Date: Jun 2015
Published By: GBI Research

Price: $6995
Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation
Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant. GBI Research analysis identified 59 first-in-class programs in the asthma pipeline, acting on 43 first-in-class molecular targets, accounting for 23% of all products with a disclosed molecular target and reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as, despite the high clinical trial attrition rate, it is highly likely that many of the first-in-cl
Published Date: May 2015
Published By: GBI Research

Price: $6995
Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth
GBI Research, the leading business intelligence provider, has released its latest research, ""Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth"", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house
Published Date: May 2015
Published By: GBI Research

Price: $4995
Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
Highly Innovative and Diverse Pipeline The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development. GBI Research’s analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets. This exceptional first-in-class innovation is largely due to the high number of first-in-class products solely targeting the dystrophin gene, which is the primary genetic cause of DMD and BMD. The strong presence of first-in-class products in the pipeline therefore creates a distinctly different landscape to the market landscape, which relies on symptomatic treatment glucocorticoids. Although Translarna (ataluren) is
Published Date: May 2015
Published By: GBI Research

Price: $6995
Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth
GBI Research, the leading business intelligence provider, has released its latest research: ‘Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth’, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary resea
Published Date: May 2015
Published By: GBI Research

Price: $4995
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
GBI Research, the leading business intelligence provider, has released its latest research, ""Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs"", which provides in-depth analysis of Rheumatoid Arthritis (RA) market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2014, along with market forecast until 2021. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the RA market in the APAC region amounted to an estimated $5.6 billion in 2014 and is expected to register a
Published Date: May 2015
Published By: GBI Research

Price: $4995
MRI Systems Market to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies
GBI Researchs report, "MRI Systems Market to 2020 Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies" discusses the market, competitive landscape, and trends for three MRI systems market segments: High-field, Mid-field, and Low-field MRI systems. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the market. The report also reviews the competitive landscape, analyzes each segments pipeline products and gives details of important merger and acquisition deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. Scope The report analyzes the MRI syst
Published Date: Apr 2015
Published By: GBI Research

Price: $3500
Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 - Asia-Pacific
GBI Researchs report, "Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 Asia-Pacific" provides quantitative analysis of the four multiparameter patient monitoring devices market segments: high acuity monitors, mid acuity monitors, low acuity monitors and multiparameter central stations. The analysis includes market size data by revenue and volume over the 20062020 period for the following countries: Australia, Japan, China and India. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. Scope Information on market size for the four multiparameter patient monitoring devices market segments: high acuity monitors, mid acuity monitors, low acuity monitors
Published Date: Apr 2015
Published By: GBI Research

Price: $1750
Market Digest: Ultrasound Systems Market 2006 to 2020 - Americas
GBI Research’s report, ""Market Digest: Ultrasound Systems Market 2006 to 2020 Americas"" provides quantitative analysis of the two ultrasound systems market segments: stand-alone systems and portable systems. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: US, Brazil and Canada. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope The report includes  Information on market size for the two ultrasound systems market segments: stand-alone systems and portable systems. Annualized sales data by revenue for the 2006–2020 period Annualized sales data by volume for the 2
Published Date: Mar 2015
Published By: GBI Research

Price: $1750
Market Digest: Ultrasound Systems Market 2006 to 2020 - Asia-Pacific
GBI Researchs report, "Market Digest: Ultrasound Systems Market 2006 to 2020 Asia-Pacific" provides quantitative analysis of the two ultrasound systems market segments: stand-alone systems and portable systems. The analysis includes market size data by revenue and volume over the 20062020 period for the following countries: China, Japan, India and Australia. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. Scope The report includes  Information on market size for the two ultrasound systems market segments: stand-alone systems and portable systems. Annualized sales data by revenue for the 20062020 period Annualized sales data by volume for the 20062020 period
Published Date: Mar 2015
Published By: GBI Research

Price: $1750
Market Digest: Ultrasound Systems Market 2006 to 2020 - Europe
GBI Researchs report, "Market Digest: Ultrasound Systems Market 2006 to 2020 Europe" provides quantitative analysis of the two ultrasound systems market segments: stand-alone systems and portable systems. The analysis includes market size data by revenue and volume over the 20062020 period for the following countries: Germany, France, UK, Italy and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts Scope The report includes  Information on market size for the two ultrasound systems market segments: stand-alone systems and portable systems. Annualized sales data by revenue for the 20062020 period Annualized sales data by volume for the 20062020 period Co
Published Date: Mar 2015
Published By: GBI Research

Price: $1750
Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations
GBI Research, a leading business intelligence provider, has released its latest research report,""Asthma Therapeutics in Major Developed Markets to 2020  Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations"".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence. The glob
Published Date: Feb 2015
Published By: GBI Research

Price: $4995
Asthma Therapeutics Market to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations
GBI Research, a leading business intelligence provider, has released its latest research report: “Asthma Therapeutics Market to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations.” The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence. The global preval
Published Date: Feb 2015
Published By: GBI Research

Price: $6995
Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation
Large and Innovative Pipeline The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and the concomitant mechanisms of action. Moderate-to-severe pain continues to be dominated by opioids that are increasingly being reformula
Published Date: Feb 2015
Published By: GBI Research

Price: $6995
Market Digest: Aesthetic Lasers and Energy Devices Market 2006 to 2020 - Americas
GBI Researchs report, "Market Digest: Aesthetic Lasers and Energy Devices Market 2006 to 2020 Americas" provides quantitative analysis of the three aesthetic lasers and energy devices market segments: minimally invasive body contouring devices, non-invasive body contouring devices and laser resurfacing devices. The analysis includes market size data by revenue and volume over the 20062020 period for the following countries: US, Brazil, Mexico and Canada. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. Scope Information on market size for the three aesthetic lasers and energy devices market segments: minimally invasive body contouring devices, non-invasive body contou
Published Date: Feb 2015
Published By: GBI Research

Price: $1750
Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
Large and Diverse Pipeline The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market. The contrast between the market and pipeline is vast. Analysis showed that the market contains 70 products, the majority of which are generic formulations of chemotherapies that are not frequently used in treatment, particularly in advanced-stage patients. Nexavar (sorafenib) is the dominant therapeutic on the market, and is also the only targeted therapy that is in regular use for advanced-stage liver cancer patients. However, pi
Published Date: Jan 2015
Published By: GBI Research

Price: $6995
Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches
GBI Research, a leading business intelligence provider, has released its latest research report: “Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches”. The report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC). Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-lin
Published Date: Jan 2015
Published By: GBI Research

Price: $4995
Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics
GBI Research, the leading business intelligence provider, has released its latest research: “Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics”, which provides in-depth analysis of the Colorectal Cancer (CRC) therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis. The CRC therapeutics market in the eight major markets is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.8% to $9.4 billion b
Published Date: Jan 2015
Published By: GBI Research

Price: $4995
Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 - Europe (Germany, France, Italy, UK and Spain)
GBI Research’s report, ""Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 Europe (Germany, France, Italy, UK and Spain)” provides quantitative analysis of the four multiparameter patient monitoring devices market segments: high acuity monitors, mid acuity monitors, low acuity monitors and multiparameter central stations. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: Germany, France, UK, Italy and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the four multiparameter patient monitoring devices market segments: h
Published Date: Dec 2014
Published By: GBI Research

Price: $1750
Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth
GBI Research, the leading business intelligence provider, has released its latest research, “Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 Increasing Uptake of Novel Drug Classes to Drive Market Growth”, which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research&rsqu
Published Date: Nov 2014
Published By: GBI Research

Price: $4995
Market Snapshot: Aesthetic Lasers and Energy Devices Market 2006 to 2020 - Asia-Pacific
GBI Research’s report, “Market Snapshot: Aesthetic Lasers and Energy Devices Market 2006 to 2020 Asia-Pacific” provides quantitative analysis of the three aesthetic lasers and energy devices market segments: minimally invasive body contouring devices, non-invasive body contouring devices and laser resurfacing devices. The analysis includes market size data by revenue and volume over the 2006 2020 period for the following countries: China, Japan, South Korea, Australia and India. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the three aesthetic lasers and energy devices market segments: minimally invasive b
Published Date: Nov 2014
Published By: GBI Research

Price: $1750
Market Digest: Aesthetic Lasers and Energy Devices Market 2006 to 2020 - Asia-Pacific
GBI Research’s report, “Market Digest: Aesthetic Lasers and Energy Devices Market 2006 to 2020 Asia-Pacific” provides quantitative analysis of the three aesthetic lasers and energy devices market segments: minimally invasive body contouring devices, non-invasive body contouring devices and laser resurfacing devices. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: Australia, China, India, Japan and South Korea. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the three aesthetic lasers and energy devices market segments:  minim
Published Date: Nov 2014
Published By: GBI Research

Price: $1750
Frontier Pharma - NSCLC - Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma
Large Degree of Innovation in NSCLC Pipeline The NSCLC pipeline currently has 389 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market comprises primarily ineffective chemotherapies that target tubulin or DNA replication, the pipeline shows an incredibly diverse range of therapies targeting multiple signaling pathways and molecules integral to cancer development. This diversity is partially due to the presence of 122 first-in-class products, which accounts for 38% of the overall pipeline therapies that disclosed their target. In an industry, market and development landscape that favors first-in-class over non-first-in-class development in many ways, such as throu
Published Date: Oct 2014
Published By: GBI Research

Price: $6995
Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies
GBI Research, the leading business intelligence provider, has released its latest research: ‘Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies ’, which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan.  It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer (CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is expected to
Published Date: Oct 2014
Published By: GBI Research

Price: $4995
Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options
GBI Research, a leading business intelligence provider, has released its latest research report: “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options”, which provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan and Canada. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). The value of the NHL market is expected to reach $9
Published Date: Oct 2014
Published By: GBI Research

Price: $4995
Market Snapshot: Cardiac Rhythm Management Devices 2006 to 2020 - US and Europe (US, Germany, France, Italy, UK, Spain)
GBI Research’s report, “Market Snapshot: Cardiac Rhythm Management Devices 2006 to 2020 US and Europe (US, Germany, France, Italy, UK, Spain)” provides quantitative analysis of the four cardiac rhythm management devices market segments: : cardiac resynchronization therapy devices, implantable cardioverter defibrillators, implantable loop recorders and pacemakers. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: US, Germany, France, Italy, UK and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the four cardiac rhythm management de
Published Date: Oct 2014
Published By: GBI Research

Price: $1750
Market Digest: Cardiac Rhythm Management Devices 2006 to 2020 - US and Europe (US, Germany, France, Italy, UK, Spain)
GBI Research’s report, “Market Digest: Cardiac Rhythm Management Devices 2006 to 2020 US and Europe (US, Germany, France, Italy, UK, Spain)” provides quantitative analysis of the four cardiac rhythm management devices market segments: : cardiac resynchronization therapy devices, implantable cardioverter defibrillators, implantable loop recorders and pacemakers. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: US, Germany, France, Italy, UK and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the four cardiac rhythm management device
Published Date: Oct 2014
Published By: GBI Research

Price: $1750
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries
GBI Research, the leading business intelligence provider, has released its latest research, ‘Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries’, which provides insights into Major Depressive Disorder (MDD) in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of the pipeline, clinical trial failure rate and deal analysis for MDD. The report is built using data and information sourced from proprietary databases, primary and secon
Published Date: Oct 2014
Published By: GBI Research

Price: $4995
Market Digest: Aesthetic Lasers and Energy Devices Market 2006 to 2020 - Europe (Germany, France, Italy, UK, Spain)
The report covers the Europe (Germany, France, Italy, UK and Spain) aesthetic lasers and energy devices market revenue and volume for the following segments: Minimally Invasive Body Contouring (MIBC) Devices, Non-Invasive Body Contouring (NIBC) Devices and Laser Resurfacing (LR) Devices. The report also provides company shares by revenue for the above mentioned countries for the year 2013. Scope Information on market size for the three aesthetic lasers and energy devices market segments: minimally invasive body contouring devices, non-invasive body contouring devices and laser resurfacing devices. Annualized sales data by revenue for the 2006–2020 period and company share data by revenue for 2013 Annualized sales data by volume for the 2006–2020 period Coverage o
Published Date: Oct 2014
Published By: GBI Research

Price: $1750
Market Snapshot: Aesthetic Lasers and Energy Devices Market 2006 to 2020 - Europe (Germany, France, Italy, UK, Spain)
GBI Research’s report, “Market Snapshot: Aesthetic Lasers and Energy Devices Market 2006 to 2020 - Europe (Germany, France, Italy, UK, Spain)” provides quantitative analysis of the three aesthetic lasers and energy devices market segments: minimally invasive body contouring devices, non-invasive body contouring devices and laser resurfacing devices. The analysis includes market size data by revenue and volume over the 2006-2020 period for the following countries: Germany, France, Italy, UK and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.  Scope Information on market size for the three aesthetic lasers and energy devices market segm
Published Date: Oct 2014
Published By: GBI Research

Price: $1750
Picture Archiving and Communication Systems Market to 2020 - Digitization of Healthcare Systems and Evolution of PACS as a Decision Support Tool Drive Growth
GBI Research’s report, “Picture Archiving and Communication Systems Market to 2020 - Digitization of Healthcare Systems and Evolution of PACS as a Decision Support Tool Drive Growth” discusses the market, competitive landscape, and trends for two Picture Archiving and Communications Systems (PACS) market segments: radiology PACS and cardiology PACS. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the overall market. The report also reviews the competitive landscape, analyzes pipeline products by segment and gives details of important Merger and Acquisition (M&A) deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house ana
Published Date: Oct 2014
Published By: GBI Research

Price: $3500
Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth
GBI Research, a leading business intelligence provider, has released its latest research report “Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth.” Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90–95% of all melanomas. Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity
Published Date: Sep 2014
Published By: GBI Research

Price: $4995
Acute Myeloid Leukemia Therapeutics Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts
GBI Research, has released its latest pharma report - “Acute Myeloid Leukemia Therapeutics Market to 2020: Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts’. Treatment and prognosis in AML is strongly influenced by a patient’s age, and their cytogenetic profile. In the majority of cases these two prognostic influences are linked, with a higher frequency of unfavorable cytogenetic abnormalities observed in the elderly. Survival in this cohort of elderly patients is very poor, with a five year overall survival of 3–8% (Luger, 2010). Despite a relatively advanced understanding of genetic abnormalities associated with AML, the introduction of targeted therapies is lagging in this indication in comparison to other cancers such as breast and lung canc
Published Date: Sep 2014
Published By: GBI Research

Price: $4995
Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting
GBI Research, the leading business intelligence provider, has released its latest research: ‘Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting ’, which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a
Published Date: Sep 2014
Published By: GBI Research

Price: $4995
Market Snapshot: Mammography Systems 2006 to 2020 - Americas (US, Canada, Brazil, Mexico)
GBI Research’s report, “Market Snapshot: Mammography Systems 2006 to 2020 Americas (US, Canada, Brazil, Mexico)” provides quantitative analysis of the two mammography systems market segments: full field mammography systems and film-screen mammography systems. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: the US, Canada, Brazil and Mexico It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two mammography systems market segments: full field mammography systems and film-screen mammography systems Annualized sales data by revenue for
Published Date: Sep 2014
Published By: GBI Research

Price: $1750
Market Digest: Mammography Systems 2006 to 2020 - Americas (US, Canada, Brazil, Mexico)
GBI Research’s report, “Market Digest: Mammography Systems 2006 to 2020 Americas (US, Canada, Brazil, Mexico)” provides quantitative analysis of the two mammography systems market segments: full field mammography systems and film-screen mammography systems. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: the US, Canada, Brazil and Mexico It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two mammography systems market segments: full field mammography systems and film-screen mammography systems Annualized sales data by revenue for t
Published Date: Sep 2014
Published By: GBI Research

Price: $1750
Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM
GBI Research, the leading business intelligence provider, has released its latest research: ‘Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM’, which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products. The value of the GBM market in the APAC region amounted to an estimated $49.4m in 2013, and is expected to register a Compoun
Published Date: Aug 2014
Published By: GBI Research

Price: $3500
Market Digest: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain)
GBI Research’s report, “Market Digest: Transcatheter Heart Valve 2007 to 2020 Europe (Germany, France, Italy, UK, Spain)” provides quantitative analysis of the transcatheter heart valves market in Europe. The analysis includes market size data by revenue and volume over the 2007–2020 period and key company share data by revenue in 2013 for the following countries: Germany, France, Italy, UK, Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the transcatheter heart valves Annualized sales data by revenue for the 2007–2020 period and company share data by revenue for 2013 Annualized sales
Published Date: Aug 2014
Published By: GBI Research

Price: $1750
Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe
GBI Research’s report: “Transcatheter Heart Valve 2007 to 2020 – Europe” provides quantitative analysis of the transcatheter heart valves market in Europe. The analysis includes market size data by revenue and volume over the 2007–2020 period and key company share data by revenue in 2013 for the following countries: Germany, France, Italy, UK, Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the transcatheter heart valves Annualized sales data by revenue for the 2007–2020 period and company share data by revenue for 2013 Annualized sales data by volume for the 2007–2020 period
Published Date: Aug 2014
Published By: GBI Research

Price: $1750
Ventilators Market to 2020 - Technical Advances and Hospital Expansion Serve as Distinct Regional Growth Drivers
Ventilators Market to 2020” discusses the market, competitive landscape, and trends for three ventilator market segments: Adult/pediatric, neonatal and transport ventilators. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the market. The report also reviews the competitive landscape, analyzes pipeline products by segment and gives details of important merger and acquisition deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Key geographies: US, Canada, Brazil, UK, Germany, France, Italy, Spain, Japan, China, India and Australia Information on market size f
Published Date: Aug 2014
Published By: GBI Research

Price: $3500
Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market
GBI Research, a leading business intelligence provider, has released its latest research report, “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market”. The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment. The report focuses on the increasing differentiation between the three ma
Published Date: Jul 2014
Published By: GBI Research

Price: $3500
Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation
Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical industry with 815 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; GBI Research analysis identified 253 first-in-class programs in the breast cancer pipeline, acting on 176 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as, des
Published Date: Jul 2014
Published By: GBI Research

Price: $6995
Market Digest: Transcatheter Heart Valves 2007 to 2020 - Americas (US, Canada, Brazil, Mexico)
GBI Research’s report, “Market Digest: Transcatheter Heart Valves 2007 to 2020 Americas (US, Canada, Brazil, Mexico)” provides quantitative analysis of the transcatheter heart valves market in Americas. The analysis includes market size data by revenue and volume over the 2007–2020 period and key company share data by revenue in 2013 for the following countries: US, Canada, Brazil and Mexico. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the transcatheter heart valves Annualized sales data by revenue for the 2007–2020 period and company share data by revenue for 2013 Annualized sales data b
Published Date: Jul 2014
Published By: GBI Research

Price: $1750
Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market
GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates. The total value of the critical care market in the major developed markets was estimated at $1.8 b
Published Date: Jul 2014
Published By: GBI Research

Price: $3500
Market Snapshot: Transcatheter Heart Valves 2007 to 2020 - Americas
GBI Research’s report: “Transcatheter Heart Valves 2007 to 2020 – Americas” provides quantitative analysis of the transcatheter heart valves market in Americas. The analysis includes market size data by revenue and volume over the 2007–2020 period and key company share data by revenue in 2013 for the following countries: US, Canada, Brazil and Mexico. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the transcatheter heart valves Annualized sales data by revenue for the 2007–2020 period and company share data by revenue for 2013 Annualized sales data by volume for the 2007–2020 per
Published Date: Jul 2014
Published By: GBI Research

Price: $1750
Market Snapshot: Mammography Systems 2006 to 2020 - Europe (Germany, UK, France, Italy, Spain)
GBI Research’s report, “Market Snapshot: Mammography Systems 2006 to 2020 - Europe (Germany, UK, France, Italy, Spain)” provides quantitative analysis of the two mammography systems market segments: full field mammography systems and film-screen mammography systems. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: Germany, UK, France, Italy and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two mammography systems market segments: full field mammography systems and film-screen mammography systems Annualized sales data b
Published Date: Jul 2014
Published By: GBI Research

Price: $1750
Market Digest: Mammography Systems 2006 to 2020 - Europe (Germany, UK, France, Italy, Spain)
GBI Research’s report, “Market Digest: Mammography Systems 2006 to 2020 Europe (Germany, UK, France, Italy, Spain)” provides quantitative analysis of the two mammography systems market segments: full field mammography systems and film-screen mammography systems. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: Germany, UK, France, Italy and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two mammography systems market segments: full field mammography systems and film-screen mammography systems Annualized sales data by reve
Published Date: Jul 2014
Published By: GBI Research

Price: $1750
Market Snapshot: Glucose Monitoring Devices 2006 to 2020 - Benelux and Scandinavia (Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway)
GBI Research’s report, ""Market Digest: Glucose Monitoring Devices 2006 to 2020 Benelux and Scandinavia (Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway)” provides quantitative analysis of the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips. The analysis includes market size data by revenue and volume over the 2006–2020 period and key company share data by revenue and volume in 2013 for the following countries: are Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two glucose moni
Published Date: Jun 2014
Published By: GBI Research

Price: $1750
Market Digest: Mammography Systems 2006 to 2020 - Asia-Pacific (China, Japan, South Korea, Australia, India)
GBI Research’s report, “Market Digest: Mammography Systems 2006 to 2020 Asia-Pacific (China, Japan, South Korea, Australia, India)” provides quantitative analysis of the two mammography systems market segments: full field mammography systems and film-screen mammography systems. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: China, Japan, South Korea, Australia and India. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two mammography systems market segments: full field mammography systems and film-screen mammography systems
Published Date: Jun 2014
Published By: GBI Research

Price: $1750
Market Snapshot: Glucose Monitoring Devices 2006 to 2020 - Benelux and Scandinavia (Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway)
Market Snapshot: Glucose Monitoring Devices 2006 to 2020 Benelux and Scandinavia (Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway)” provides quantitative analysis of the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips. The analysis includes market size data by revenue and volume over the 2006–2020 period and key company share data by revenue and volume in 2013 for the following countries: are Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two glucose monitoring devices market segments:
Published Date: Jun 2014
Published By: GBI Research

Price: $1750
Market Snapshot: Mammography Systems 2006 to 2020 - Asia-Pacific
Mammography Systems 2006 to 2020 – Asia-Pacific provides quantitative analysis of the two mammography systems market segments: full field mammography systems and film-screen mammography systems. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: China, Japan, South Korea, Australia and India. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two mammography systems market segments: full field mammography systems and film-screen mammography systems Annualized sales data by revenue for the 2006–2020 period and company share data by revenue f
Published Date: Jun 2014
Published By: GBI Research

Price: $1750
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
GBI Research, a leading business intelligence provider, has released its latest research report: “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany”. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck’s Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche’s Avastin (bevacizumab), carmustine and other c
Published Date: Jun 2014
Published By: GBI Research

Price: $3500
Market Snapshot: Glucose Monitoring Devices 2014 - Benelux and Scandinavia
GBI Research’s report: “Glucose Monitoring Devices 2014 – Benelux and Scandinavia” provides quantitative analysis of the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips. The analysis includes market size data by revenue and volume over the 2006–2020 period and key company share data by revenue and volume in 2013 for the following countries: are Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two glucose monitoring devices market segments: blood glucose meters and blood glucose te
Published Date: Jun 2014
Published By: GBI Research

Price: $3500
Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries
GBI Research, the leading business intelligence provider, has released its latest research: ‘Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 – Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries ’, which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the hypertension market in the major developed markets amounted to an estimated $4
Published Date: Jun 2014
Published By: GBI Research

Price: $3500
Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs
GBI Research, the leading business intelligence provider, has released its latest research: ‘Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs ’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the eight major markets – The US, The UK, Franc
Published Date: Jun 2014
Published By: GBI Research

Price: $3500
Market Snapshot: Glucose Monitoring Devices 2006 to 2020 - Southeast Asia (Taiwan, Indonesia, Malaysia, Singapore, Vietnam)
GBI Research’s report, ""Market Digest: Glucose Monitoring Devices 2006 to 2020 Southeast Asia (Taiwan, Indonesia, Malaysia, Singapore, Vietnam)” provides quantitative analysis of the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips. The analysis includes market size data by revenue and volume over the 2006–2020 period and key company share data by revenue and volume in 2013 for the following countries: Taiwan, Indonesia, Malaysia, Singapore and Vietnam. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two glucose monitoring devices market segments: bloo
Published Date: May 2014
Published By: GBI Research

Price: $1750
Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation
Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly impairs the patient’s physical and mental wellbeing. The primary cause of psoriasis is unknown, as are the mechanisms that lead to immune cells directing inflammatory responses towards the skin. Within the lucrative autoimmune market, the psoriasis market has grown considerably due to the repositioning of all three marketed Tumor Necrosis Factor (TNF) inhibitors: Humira (adalimumab) and Enbrel (etanercept) which were originally approved for rheumatoid arthritis, and also Remicade (infliximab), th
Published Date: May 2014
Published By: GBI Research

Price: $3500
Market Snapshot: Glucose Monitoring Devices 2014 - Southeast Asia
GBI Research’s report: "Market Snapshot: Glucose Monitoring Devices 2014 - Southeast Asia” provides quantitative analysis of the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips. The analysis includes market size data by revenue and volume over the 2006–2020 period and key company share data by revenue and volume in 2013 for the following countries: Taiwan, Indonesia, Malaysia, Singapore and Vietnam. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Information on market size for the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips Annualized
Published Date: May 2014
Published By: GBI Research

Price: $1750
Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets
GBI Research’s report: “Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets” discusses the market, competitive landscape, and trends for two facial aesthetics market segments: Botox and dermal fillers. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the market. The report also reviews the competitive landscape, analyzes each segment’s pipeline products and gives details of important merger and acquisition deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope
Published Date: May 2014
Published By: GBI Research

Price: $3500